The stock of Gilead Sciences, Inc. (NASDAQ:GILD) last traded at $79.02, up 0.87% from the previous session.
As we calculate the median target price by taking the range between a high of $116.00 and a low of $71.00, we find $90.10. Given the previous closing price of $78.34, this indicates a potential upside of 15.01 percent. GILD stock price is now 2.93% away from the 50-day moving average and 0.87% away from the 200-day moving average. The market capitalization of the company currently stands at $98.46B.
Brokers who have rated the stock have averaged $89.82 as their price target over the next twelve months.
With the price target of $75, Deutsche Bank recently initiated with Hold rating for Gilead Sciences, Inc. (NASDAQ: GILD).
In other news, Dickinson Andrew D, Chief Financial Officer sold 5,000 shares of the company’s stock on Oct 17. The stock was sold for $400,017 at an average price of $80.00. Upon completion of the transaction, the Chief Financial Officer now directly owns 104,003 shares in the company, valued at $8.22 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 12, Chief Medical Officer Parsey Merdad sold 1,501 shares of the business’s stock. A total of $115,562 was realized by selling the stock at an average price of $76.99. This leaves the insider owning 70,130 shares of the company worth $5.54 million. Insiders disposed of 218,077 shares of company stock worth roughly $17.23 million over the past 1 year. A total of 0.09% of the company’s stock is owned by insiders.
With an opening price of $78.37 on Tuesday morning, Gilead Sciences, Inc. (NASDAQ: GILD) set off the trading day. During the past 12 months, Gilead Sciences, Inc. has had a low of $72.87 and a high of $89.74. As of last week, the company has a debt-to-equity ratio of 1.12, a current ratio of 1.34, and a quick ratio of 1.20. According to the stock market information, the enterprise value for the company is $115.72B, which is based on a 16.94 price-to-earnings ratio, a 4.11 price-to-earnings-growth ratio, and a beta of 0.24. The fifty day moving average price for GILD is $76.77 and a two-hundred day moving average price translates $78.34 for the stock.
The latest earnings results from Gilead Sciences, Inc. (NASDAQ: GILD) was released for Sep, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $2.29, beating analysts’ expectations of $1.92 by 0.37. This compares to $1.42 EPS in the same period last year. The net profit margin was 21.55% and return on equity was 27.08% for GILD. The company reported revenue of $7.05 billion for the quarter, compared to $7.04 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 0.13 percent. For the current quarter, analysts expect GILD to generate $7.08B in revenue.
